Recent News Releases

CSL Seqirus will provide its registered pandemic influenza vaccine to the UK if an influenza pandemic occurs during the next four years. This new agreement to CSL Seqirus follows more than ten...

CSL Seqirus presents new data at the 9th ESWI meeting on the impact of effective vaccination campaigns to protect healthcare systems across the world.1,2 The French data highlights how vaccines...

SUMMIT, N.J., September 15, 2023 -- CSL Seqirus, a business of CSL (ASX:CSL), today announced new data that will be presented at the European Scientific Working Group on Influenza (ESWI)...

EMA application supported by Phase 3 primary vaccination study demonstrating primary efficacy endpoint was met An additional Phase 3 booster study demonstrating non-inferiority of immune response...

The 2023 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) include upgraded recommendations for intravenous (IV) iron supplementation, including Ferinject®...

Melbourne, Australia – 21 August 2023 – Australia today ushered in a new era in scientific and medical innovation, with Prime Minister of Australia, Anthony Albanese officially opening CSL’s...

Global biotechnology leader CSL (ASX: CSL) (USOTC: CSLLY) announced today that Jeffrey Ball, an established global leader across multiple disciplines and functions, has been appointed Chief...

CSL Seqirus is the only influenza vaccine manufacturer that offers differentiated vaccine options for individuals six months of age and older. Since the COVID-19 pandemic, there has been a...

HEMGENIX®, the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX levels for years, significantly reduce the rate of annual bleeds versus...

Injectafer® (ferric carboxymaltose) is now the first and only intravenous (i.v.) iron replacement therapy in the U.S. indicated for improvement in exercise capacity in adult patients with...